PharmGen Science
004720
Company Profile
Business description
PharmGen Science is a Korea-based company engaged in the business divisions of pharmaceutical business, healthcare business, and other businesses. The pharmaceutical business provides Prescription drugs such as digestive medicines, over-the-counter drugs, obesity treatments, etc; the Healthcare business operates in Health functional foods, beauty products; and Other businesses include Real estate rental business. The group generates the majority of its revenue from the pharmaceutical business.
Contact
50, Yakjakgongdan 2-gil
Hyangnam-eup
Gyeonggi-do
Hwaseong-si18622
KORT: +82 221943532
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
235
Stocks News & Analysis
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,080.80 | 68.20 | 0.76% |
| CAC 40 | 7,970.00 | 83.04 | 1.05% |
| DAX 40 | 26,039.68 | 335.66 | 1.31% |
| Dow JONES (US) | 52,342.56 | 132.54 | -0.25% |
| FTSE 100 | 10,722.07 | 27.57 | 0.26% |
| HKSE | 22,958.65 | 136.18 | -0.59% |
| NASDAQ | 26,184.72 | 365.13 | -1.38% |
| Nikkei 225 | 64,659.47 | 705.28 | 1.10% |
| NZX 50 Index | 13,775.21 | 65.04 | 0.47% |
| S&P 500 | 7,720.39 | 23.59 | -0.30% |
| S&P/ASX 200 | 8,961.30 | 69.50 | 0.78% |
| SSE Composite Index | 3,651.43 | 30.04 | -0.82% |